Beryl Drugs Ltd Stock Price Today (NSE: BERLDRG)
Fundamental Score
Beryl Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Beryl Drugs Ltd share price today is ₹21.49, up +1.46% on NSE/BSE as of 18 June 2026. Beryl Drugs Ltd (BERLDRG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹11.54 (Cr). The 52-week high for BERLDRG share price is ₹30.00 and the 52-week low is ₹15.92. At a P/E ratio of 50.15x, BERLDRG is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.30% and a debt-to-equity ratio of 0.45.
Beryl Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Beryl Drugs Ltd share price chart: -8.94% return over the past month. 52-week high ₹30.00, 52-week low ₹15.92.
Beryl Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹21.18 | ₹21.61 | ₹21.18 | ₹21.49 | 347.00 (Cr) | |
| ₹21.86 | ₹21.86 | ₹19.80 | ₹21.18 | 1.24K (Cr) | |
| ₹20.84 | ₹20.84 | ₹20.84 | ₹20.84 | 1.90K (Cr) | |
| ₹19.10 | ₹19.85 | ₹19.06 | ₹19.85 | 420.00 (Cr) | |
| ₹19.03 | ₹19.96 | ₹19.01 | ₹19.03 | 1.21K (Cr) | |
| ₹20.80 | ₹20.80 | ₹19.01 | ₹19.01 | 310.00 (Cr) | |
| ₹19.43 | ₹20.90 | ₹19.42 | ₹19.81 | 4.70K (Cr) | |
| ₹19.20 | ₹20.50 | ₹19.10 | ₹20.44 | 4.92K (Cr) | |
| ₹20.15 | ₹20.15 | ₹20.10 | ₹20.10 | 681.00 (Cr) | |
| ₹21.60 | ₹21.60 | ₹20.10 | ₹20.10 | 318.00 (Cr) |
Beryl Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹21.86 | ₹21.86 | ₹19.80 | ₹21.49 | -1.69% | |
| ₹20.86 | ₹22.89 | ₹19.01 | ₹20.84 | -0.10% | |
| ₹18.05 | ₹27.09 | ₹18.05 | ₹21.80 | +20.78% | |
| ₹20.69 | ₹22.34 | ₹15.92 | ₹19.28 | -6.81% | |
| ₹22.50 | ₹23.00 | ₹19.55 | ₹20.19 | -10.27% | |
| ₹23.47 | ₹23.95 | ₹21.01 | ₹21.99 | -6.31% | |
| ₹22.75 | ₹24.00 | ₹21.00 | ₹23.40 | +2.86% | |
| ₹23.50 | ₹24.75 | ₹20.50 | ₹22.71 | -3.36% | |
| ₹22.24 | ₹27.60 | ₹21.85 | ₹24.03 | +8.05% | |
| ₹25.99 | ₹27.49 | ₹20.11 | ₹22.24 | -14.43% | |
| ₹21.21 | ₹30.00 | ₹18.39 | ₹25.22 | +18.91% | |
| ₹21.72 | ₹23.92 | ₹19.94 | ₹21.21 | -2.35% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Overvalued micro-cap turnaround story with stagnant recent performance and illiquidity risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Beryl Drugs convened an EOGM on May 11, 2026, to approve the regularization of directors and a related party transaction. No share transfer activities occurred during the quarter ended March 31, 2026.
CORE STORY (THE REAL GAME)
Beryl Drugs is a micro-cap domestic pharma play. The market is likely viewing it as a turnaround story, given the historical EPS growth, but recent lack of profit growth raises concerns.
- EOGM on May 11, 2026, for related party transaction approval
- Stock upgraded to sell on technical improvements despite flat financials
- India Pharma 2026 concludes with a strong push for enhanced funding, infrastructure and speed to accelerate pharmaceutical innovation
- Significant order wins
- Consistent quarterly profit growth
- Successful integration of related party transaction
- Micro/SME cap: Illiquidity risk
- Overvalued: P/E 50.15x vs Industry P/E 31.77x
- Zero share transfer activity: Liquidity concerns
No FII/DII presence. Promoter holding stable at 26.38%.
India Pharma 2026 highlighting the need for enhanced funding and infrastructure could be a tailwind.
Yes: Free Cash Flow 5Y: ₹2.77 Cr
Monitor for consistent profit growth and successful related party transaction integration. A sustained turnaround is needed to justify the current valuation.
Primary Thesis Risk
Failure to achieve consistent profit growth will lead to valuation collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Beryl Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Beryl Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BERLDRG across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Excellent EPS Growth (63.26% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (63.26% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (6.30%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 50.15x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Revenue Contraction (-8.51%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Low Promoter Commitment (26.38%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Beryl Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Beryl Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Beryl Drugs LtdBeryl Drugs Ltd...Selected✓ BERLDRG • 524606 | 27.4/100 | ₹21.49₹21 | ₹11.54₹11.54 | 50.15Average 50.1 Average | 6.30%Poor 6.30% Poor | 10.15%Average 10.15% Average | 0.45Excellent 0.5 Excellent | 63.26%Excellent 63.26% Excellent | 10.60%Good 10.60% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1798.70₹1799 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.50₹1391 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1292.40₹1292 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2267.50₹2268 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1092.90₹1093 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.60₹2321 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5322.50₹5323 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Beryl Drugs Ltd PE Ratio History
Historical price-to-earnings ratio for BERLDRG — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.52 | ₹36.15 | 23.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Beryl Drugs Ltd Quarterly Performance
Latest quarterly metrics for BERLDRG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-8.51%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
0.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.60%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
63.26%
Compounded annual net profit growth over 5 years
Beryl Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BERLDRG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Beryl Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Beryl Drugs Ltd (BERLDRG) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Beryl Drugs Ltd
About BERLDRG (Beryl Drugs Ltd)
Beryl Drugs Ltd is a dynamic pharmaceutical entity rooted in the heart of India, dedicated to the development, production, and distribution of a diverse range of pharmaceutical sol...utions. Driven by a commitment to improving healthcare outcomes, the company meticulously crafts both branded and generic formulations, ensuring access to essential medicines for a wide spectrum of patients. Beyond traditional pills and tablets, Beryl Drugs specializes in sophisticated delivery systems including intravenous fluids and small volume injectables in both liquid and lyophilized forms. This comprehensive approach extends to specialized areas such as ophthalmic and otic solutions, alongside a dedicated line of veterinary products, solidifying its position as a versatile player in the pharmaceutical landscape. At the core of Beryl Drugs lies a robust infrastructure encompassing cutting-edge research and development capabilities. This investment in innovation fuels the creation of novel drug formulations and delivery methods, ensuring the company remains at the forefront of pharmaceutical advancements. Supplementing its in-house production, Beryl Drugs also provides contract manufacturing services, leveraging its state-of-the-art facilities and expertise to support other pharmaceutical companies. Stringent quality control measures permeate every stage of production, guaranteeing the safety and efficacy of all products bearing the Beryl Drugs name. Furthermore, the company actively pursues export opportunities, expanding its reach and contributing to global healthcare access. Established in 1993 and headquartered in the bustling city of Indore, Beryl Drugs Ltd has steadily grown to become a respected name in the Indian pharmaceutical industry. The company's success is built upon a foundation of ethical business practices, a skilled workforce, and a steadfast dedication to meeting the evolving needs of the healthcare sector. Through continuous investment in research, technology, and talent, Beryl Drugs remains poised to further its mission of providing high-quality, affordable medicines to improve the lives of people and animals, both domestically and internationally. Its long-standing presence in the market reflects its reliability and commitment to sustained growth and innovation.
Company Details
Key Leadership
BERLDRG Share Price: Frequently Asked Questions
What is the current share price of Beryl Drugs Ltd?
Beryl Drugs Ltd (BERLDRG) trades at ₹21.49 on NSE and BSE. Market cap ₹11.54 (Cr). Educational data only.
What is the P/E ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd has a P/E of 50.15x vs industry average 31.77x.
What is the Bull Run score for Beryl Drugs Ltd?
Beryl Drugs Ltd has a Bull Run score of 27.4/100 based on 25+ financial parameters.
Does Beryl Drugs Ltd pay dividends?
Beryl Drugs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Beryl Drugs Ltd?
Beryl Drugs Ltd has ROE of 6.30%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd has debt-to-equity of 0.45.
Is Beryl Drugs Ltd a good investment?
Bull Run gives Beryl Drugs Ltd a score of 27.4/100. This is not investment advice — consult a SEBI-registered advisor.